Share

Interview with Winette van der Graaf: enhanced patient participation in trials may help make cancer research more heterogeneous

ESMO Congress 2022. Winette van der Graaf, president of EORTC, talks about the importance and challenges of placing the patient at the center of clinical trials. She states that patients are usually highly motivated to participate in clinical trials. However, several challenges, such as logistics, communication issues, and geographic distance to a trial center, may prevent them from doing so. Moreover, the current strict enrolment criteria often exclude older patients from clinical trials. The result is that trials tend to be overly homogeneous, thus limiting the generalisability of the data. With an aging population, we need more elderly patients to participate in clinical trials. Read the full article here.

Back to news list

Related News

  • EORTC Quality of Life Group unveils flexible, future-focused strategy for patient-reported outcome assessment in cancer care

  • EMA-EORTC workshop underscores critical role of patient-reported outcomes and quality of life data in regulatory decision-making

  • New study confirms link between cancer patients’ quality of life and survival

  • New Treatment for Recurrent Meningioma: LUMEN-1 Clinical Trial

  • SISAQOL-IMI Consortium Launches Final Recommendations

  • World Cancer Day 2025: EORTC’s commitment to older patients

  • EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma

  • Minister F. Vandenbroucke visits EORTC Headquarters to strengthen collaborative efforts in clinical cancer research

  • IMMUcan has completed patient enrolment

  • EORTC SPRINT clinical cancer study receives support from Rising Tide Foundation to reduce the burden for patients